Mabthera (Rituximab 100mg Injection)

Mabthera (Rituximab 100mg Injection)
MabThera (Rituximab)belongs to a group of cancer drugs known as monoclonal antibodies|.
Monoclonal antibodies recognise and lock onto specific proteins on the surface of cancer cells. This helps the body's immune system to recognise the cancer cells and destroy them. Monoclonal antibodies are sometimes called targeted therapies because they target cancer cells.
Mabthera (Rituximab 100mg Injection) works
MabThera (Rituximab) locks onto a protein called CD20, which is found on the surface of white blood cells called B-lymphocytes or B-cells. This triggers the body’s immune system to attack the cells and destroy them.
As well as being found on the surface of normal B-cells, CD20 is also present on most of the abnormal B-cells which occur in many types of non‑Hodgkin lymphoma and on some of the abnormal B-cells found in CLL.
MabThera (Rituximab) destroys both abnormal (malignant) and normal B-cells. However, the body can replace normal B-cells tha